Relevance of selectivity and non-selectivity in beta-adrenoceptor blocking drugs.

Pharmacological properties of beta-adrenoceptor blocking drugs

Beta-adrenoceptor-blocking drugs, growth hormone and acromegaly.

Chronic treatment with oxprenolol or propranolol in active hypertensive patients was associated with elevation of serum growth hormone (GH). Propranolol, 80 mg orally, caused a marked rise in GH in 3 of 4 acromegalic patients.

Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

Although beta-adrenoceptor antagonists were first developed for their potential therapeutic uses in cardiac disease, it was soon recognized during clinical trials that they had effects on the central nervous system, some ofthem unwanted, but others ofpossible therapeutic value. This paper reviews some recent developments in this area of beta-adrenoceptor clinical pharmacology, earlier studies h...

Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus.

The effects on diabetic control of the relative cardioselective beta-blocker metoprolol and the non-selective drug propranolol were compared in 20 hypertensive diabetic patients receiving diet alone or diet and oral hypoglycaemic agents. Each drug was given for one month in a double-blind, cross-over study. Fasting, noon, and mid-afternoon blood sugar concentrations rose by 1.0-1.5 mmol/l (18-2...

Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists.

We investigated the relevance of selectivity for a given alpha-1-adrenoceptor subtype for in vivo uroselectivity of several alpha-1-adrenoceptor antagonists (alfuzosin, doxazosin, prazosin, tamsulosin, terazosin and 5-Me-urapidil). Comparison of the affinities of these alpha-1-adrenoceptor antagonists at the cloned alpha-1a, alpha-1b and alpha-1d-adrenoceptor subtypes revealed that tamsulosin a...